
VIRAFIN
News: DCGI of India gave approval to the use of Antiviral drug VIRAFIN, to treat moderate COVID-19 in adults.
Virafin:
It is an Antiviral drug.
It helps patients recover faster from the COVID-19.
It helps in treating chronic hepatitis B and C patients.
It is being manufactured by Zydus Cadila.
The trials indicate that the drug was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19.
DCGI: DRUG CONTROLLER GENERAL OF INDIA
DCGI comes under the Ministry of Health and family welfare.
It comes under the gamut of Central Drug Standards Control Organisation (CDSCO).
It is responsible for approval of licenses of specialised categories of drugs which includes blood and its products, vaccines, IV fluids.
It further lays down the standards and quality of manufacturing, selling, import and distribution.
DCGI also acts as an appellate authority in case of any dispute regarding quality of drugs.
It also prepares and maintains national reference standards.
It aims to bring uniformity in enforcement of the Drugs and Cosmetics Act.
It also trains Drug Analysts deputed by State Drug Control Laboratories and other Institutions.